GenHouse reaches a major deal with HUYABIO $282M!
GenHouse Pharmaceuticals (Suzhou) Ltd. Co., a biotechnology company focusing on the development of the world’s leading small molecule anti-cancer drugs, has recently reached an exclusive license agreement with HUYA Biosciences International (HUYABIO). GenHouse granted the product development and commercialization rights of the SHP2 inhibitor GH21 outside of China to HUYABIO, who will pay upfront and milestone payments up to 282 million dollars, and GenHouse will also receive royalty payment for overseas GH21 product sales.
Dr. Kuifeng Wang, CEO of GenHouse, said that “SHP2 is a proven anti-tumor target with great potential, and its inhibition is expected to benefit many cancer patients. Data from preclinical studies show that the SHP2 inhibitor GH21 developed by GenHouse has the characteristics of strong in vivo and in vitro activities with excellent oral metabolism and good safety; clinical trials will be launched globally. We are very pleased to cooperate with HUYABIO to accelerate the clinical development and commercialization of GH21 in major global pharmaceutical markets."
Dr. Mireille Gillings, CEO and Executive Chair of HUYA Bioscience said, "We are delighted to conclude this licensing agreement with Genhouse and add such an exciting and novel product to our excellent oncology pipeline. There is a large unmet need for safer and more effective cancer treatments. GH21 data from preclinical studies have exceeded our expectations, indicating it is a promising novel compound that has the potential to treat cancer patients across many tumor types”
SHP2 is a non-receptor tyrosine phosphatase encoded by the PTPN11 gene, and it is also the first cancer-promoting phosphatase discovered in the world. In recent years, SHP2 has received widespread attention, on the one hand, SHP2 is downstream of most RTKs, mediating RTK to RAS-MAPK/PI3K-mTOR and other key signaling pathways for cell growth and survival. On the other hand, SHP2 is also downstream of immune checkpoints of PD1 and BTLA, and mediates tumor immune escape signals. Therefore, SHP2 can play a dual role in tumor targeting and tumor immunity, and is a potential anti-tumor target. In addition, the combination of SHP2 inhibitors and multiple drugs including immune checkpoint drugs has excellent effects, and it is one of the most promising targets in the anti-tumor field in recent years.
GH21, independently developed by GenHouse Pharmaceuticals with global intellectual property rights. It has strong biological activity and is effective against a variety of SHP2 point mutants. In vivo and vitro studies have shown that GH21 has no significant effects on any other phosphatases, kinases or safety related targets other than SHP2 with low off-target risks; in the meantime, it has excellent metabolism properties ,high oral bioavailability, excellent safety profile, relatively wide safety window and great development potential as a small molecule anti-tumor drug.
About GenHouse Pharmaceuticals (Suzhou) Ltd. Co.
GenHouse Pharmaceuticals is a biotechnology company focusing on the development of world’s leading anti-tumor small molecules. The core team of the company has extensive experience in new drug research and development and corporate management, has received supports from multiple investment firms. GenHouse Pharmaceutical strives to create a unique and innovative drug R&D system, focusing on the global market and forming a product pipeline with 6 high-value targeted anti-tumor varieties as the core. The company strives to adhere to the combination of basic research, innovative development, and commercialization, and quickly advance the industrialization of research results with the entrepreneurial spirit of open cooperation, and ultimately benefit the patients.
About HUYA Bioscience International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in international markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally. For more information please visit www.huyabio.com.